Trial Profile
OXEL: A Pilot Study of Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for Triple Negative Breast Cancer With Residual Disease Following Neoadjuvant Chemotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Mar 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Antineoplastics; Capecitabine
- Indications Breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms OXEL
- 13 Sep 2021 Status changed from recruiting to active, no longer recruiting.
- 26 Jun 2018 Status changed from not yet recruiting to recruiting.
- 04 May 2018 Planned initiation date changed from 1 Apr 2018 to 28 May 2018.